Literature DB >> 20878484

A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history.

Maurizio Pisanò1, Valeria Mezzolla, Maria Maddalena Galante, Giovanni Alemanno, Corrado Manca, Vito Lorusso, Antonio Malvasi, Andrea Tinelli.   

Abstract

Heterozygous germ line mutations in the Breast CAncer1 (BRCA1) and BRCA2 genes can lead to a high risk of breast and ovarian cancer, in addition to a significantly increased susceptibility of pancreatic, prostate and male breast cancer. The BRCA2 belongs to the tumor suppressor gene family and the protein encoded by this gene is involved in the repair of chromosomal damage, with an important role in the error-free repair of DNA double strand breaks. After complete sequencing of coding regions and splice junctions of both genes, in a family with breast cancer history, a non previously reported heterozygous mutation in BRCA2 was detected and studied in an Italian healthy female. The direct sequencing disclosed, on exon 15, an insertion (7525_7526insT). The frame shift mutation of BRCA2 causes a disruption of the translational reading frame, resulting in a stop codon 29 amino acids downstream, in the 2538 position of the BRCA2 protein. The mutated allele codifies a truncated protein, lacking the two putative nuclear localization signals (NLSs) that reside within the extreme C-terminal domain of BRCA2. Since this mutant protein not performs a translocation into the nucleus, it is fully non-functional.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20878484     DOI: 10.1007/s10689-010-9389-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  20 in total

1.  Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.

Authors:  B H Spain; C J Larson; L S Shihabuddin; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 2.  DNA damage hypersensitivity in cells lacking BRCA2: a review of in vitro and in vivo data.

Authors:  T Hay; A R Clarke
Journal:  Biochem Soc Trans       Date:  2005-08       Impact factor: 5.407

3.  The emerging landscape of breast cancer susceptibility.

Authors:  Michael R Stratton; Nazneen Rahman
Journal:  Nat Genet       Date:  2008-01       Impact factor: 38.330

4.  Synthetic lethality--a new direction in cancer-drug development.

Authors:  J Dirk Iglehart; Daniel P Silver
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

5.  Functional assays for classification of BRCA2 variants of uncertain significance.

Authors:  Daniel J Farrugia; Mukesh K Agarwal; Vernon S Pankratz; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Linda Wadum; Kiley Johnson; Jennifer Mentlick; Sean V Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

7.  BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.

Authors:  Haijuan Yang; Philip D Jeffrey; Julie Miller; Elspeth Kinnucan; Yutong Sun; Nicolas H Thoma; Ning Zheng; Phang-Lang Chen; Wen-Hwa Lee; Nikola P Pavletich
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

8.  BRCA2 BRC motifs bind RAD51-DNA filaments.

Authors:  Vitold E Galkin; Fumiko Esashi; Xiong Yu; Shixin Yang; Stephen C West; Edward H Egelman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

9.  CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.

Authors:  Fumiko Esashi; Nicole Christ; Julian Gannon; Yilun Liu; Tim Hunt; Maria Jasin; Stephen C West
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

View more
  5 in total

1.  Detection of false positive mutations in BRCA gene by next generation sequencing.

Authors:  Moushumi Suryavanshi; Dushyant Kumar; Manoj Kumar Panigrahi; Meenakshi Chowdhary; Anurag Mehta
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

2.  A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer.

Authors:  Jing Ma; Jichun Yang; Wenjing Jian; Xianming Wang; Deyong Xiao; Wenjun Xia; Likuan Xiong; Duan Ma
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-05       Impact factor: 4.553

Review 3.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

Review 4.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Authors:  Fatemeh Karami; Parvin Mehdipour
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

5.  Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing.

Authors:  Mojgan Ataei-Kachouei; Javad Nadaf; Mohammad Taghi Akbari; Morteza Atri; Jacek Majewski; Yasser Riazalhosseini; Masoud Garshasbi
Journal:  Iran J Public Health       Date:  2015-10       Impact factor: 1.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.